


Dear MS-SMART supporters,

We would like to thank you for your support of the MS-SMART trial. We would not be able to undertake this project without your help and support. Thus far nationally, 300 patients have been randomised. In addition 40 are fully screened and ready for randomization and a further 10 are booked for screening. This means there are still **100 places available**. With the **recruitment deadline of April 2016** fast approaching, we are eager to fill as many of these places as possible.

If you see anyone with SPMS (details below) please consider referring them to their local MS-SMART Centre. Over these final weeks, the MS-SMART core team will be making regular contact with Research Nurses, Clinical Fellows and Consultants to ensure we pre-screen every potential participant to check their suitability to invite them in for a consent and full screening visit. We will also be contacting MS Specialist Centres, Community Nurses and Allied Healthcare Professionals in the areas around the sites to raise awareness of MS-SMART and discuss potential patients for referral.



Just a reminder that MS-SMART is looking 3 drugs - **riluzone**, **fluoxetine**, or **amiloride** - versus placebo.

Inclusion Criteria

- **Aged 25-65 (inclusive) > Able to undertake MRI**
- **Diagnosis of secondary progressive MS (SPMS)**
- **Retained ability to walk > 20mtrs with bilateral support (EDSS: 4.0-6.5)**
- **Not prescribed citalopram, escitalopram, fluoxetine or sertraline**

If you know anyone who might be interested in taking part, please ask them to contact us.

Thank you in advance,

Dr Jeremy Chataway and the MS-SMART team